Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the marketing application of its Prednisolone Acetate, a chemical active pharmaceutical ingredient. This product is primarily used for treating allergic and autoimmune inflammatory diseases, and its approval is expected to enhance the company’s market position and provide significant benefits to stakeholders by expanding its product offerings in the pharmaceutical market.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in China, operating in the pharmaceutical industry. The company focuses on the production and marketing of chemical active pharmaceutical ingredients, with a market emphasis on both domestic and international sectors.
Average Trading Volume: 2,163,129
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.72B
For an in-depth examination of 0719 stock, go to TipRanks’ Overview page.